Table 1: Brief summary of novel genetic and epigenetic markers for AML, MDS, and MPN.

Study [ref#]No. of patientsMarkersDisorder

Milosevic et al. 2012 [48]203TP53, RUNX1, CBL, IDH1/2, NRAS, NPM1, and FLT3MDS, AML, and MPN
Shih et al. 2012 [49]TET2, IDH1/2, ASXL1, EZH2, and DNMT3AMDS, AML, and MPN
Patel et al. 2012 [25]398TET2, ASXL1, DNMT3A, CEBPA, PHF6, WT1, TP53, EZH2, RUNX1, PTEN FLT3, NPM1, HRAS, KRAS, NRAS, KIT, IDH1, and IDH2AML
Brecqueville et al. 2012 [41]276ASXL1, CBL, DNMT3A, IDH1/2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2MPN
Yoshida et al. 2011 [50]29U2AF35, ZRSR2, SRSF2, and SF3B1MDS
Zhang et al. 2012 [51]53SRSF2MPN and AML
Langemeijer et al. 2011 [44]151TET2AML
Schnittger et al. 2012 [52]636CBL, JAK2, and TET2MPN
Thiede 2012 [53]FLT3, NPM1, TET2, IDH1/2, and DNMT3AAML
Bejar et al. 2011 [42]439ETV6, GNAS, RUNX1, TP53, EZH2, and NRASMDS
Cimmino et al. 2011 [54]TET familyMDS, AML, and MPN